Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.

The antiphospholipid syndrome (APS) is a clinical condition whose main form of presentation is thrombosis of various vascular beds, leading to multiple complications that represent a threat to the life of patients. Therefore, the goal of this review is to present the current recommendations on the m...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:: 2022

Institución:: Pontificia Universidad Javeriana Cali

Repositorio:: Vitela

Idioma:: spa

id	Vitela2_fa4c276443118390cc63594b8d0f7fc8
oai_identifier_str	oai:vitela.javerianacali.edu.co:11522/481
network_acronym_str	Vitela2
network_name_str	Vitela
repository_id_str
spelling	Moreno-Gomez , FreddyAvendaño-Restrepo, Manuela2022-06-302023-10-11T04:35:06Z2023-10-11T04:35:06Zhttps://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/680https://vitela.javerianacali.edu.co/handle/11522/481The antiphospholipid syndrome (APS) is a clinical condition whose main form of presentation is thrombosis of various vascular beds, leading to multiple complications that represent a threat to the life of patients. Therefore, the goal of this review is to present the current recommendations on the management of the syndrome, in addition to emphasizing the existence of therapeutic alternatives other than vitamin K inhibitors. The exploration of multiple international guidelines regarding the management of APS allowed to establish that Warfarin continues to be the pillar of management for the thrombotic manifestations of the disease, and DOACs aren´t recommended for patients with APS due to recurrent thrombosis associated to this product. More clinical trials and research are required to safely recommend the use of therapies other than Warfarin in APS.El síndrome antifosfolípido (SAF) es una condición clínica cuya principal forma de presentación es la trombosis de diversos lechos vasculares, llevando a múltiples complicaciones que representan una amenaza a la vida de los pacientes. Por lo anterior se tiene como objetivo de esta revisión dar a conocer las recomendaciones más actuales sobre el manejo del síndrome, además de recalcar la existencia de alternativas terapéuticas distintas a los inhibidores de la vitamina K. La exploración de múltiples guías internacionales en cuanto al manejo del SAF permitió establecer que la Warfarina sigue siendo el pilar de manejo para las manifestaciones trombóticas de la enfermedad y que el uso de DOACs no se recomienda para el manejo debido al riesgo de trombosis recurrente asociada a su uso en pacientes con SAF. Se requiere de más ensayos clínicos e investigación para recomendar de forma segura el uso de terapias distintas a Warfarina en pacientes con SAF.application/pdfspaPontificia Universidad Javeriana Calihttps://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/680/578Derechos de autor 2023 Salutem Scientia Spiritushttps://creativecommons.org/licenses/by-nc-nd/4.0Salutem Scientia Spiritus; Vol. 8 No. 2 (2022): Revista Salutem Scientia Spiritus; 50-57Salutem Scientia Spiritus; Vol. 8 Núm. 2 (2022): Revista Salutem Scientia Spiritus; 50-572463-1426Síndrome antifosfolípidoTrombosisAnticoagulantes orales directosWarfarinaHidroxicloroquinaOmega 3Antiagregantes plaquetariosAntiphospholipid syndromeThrombosisDirect.acting oral anticoagulantsWarfarinHydroxycloroquineOmega 3AntiplateletsThrombotic events in patients with antiphospholipid syndrome and their prophylactic management.Eventos trombóticos en pacientes con síndrome antifosfolípido y su manejo profiláctico.info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisión de la literatura11522/481oai:vitela.javerianacali.edu.co:11522/4812024-06-25 05:12:42.882metadata.onlyhttps://vitela.javerianacali.edu.coRepositorio Vitelavitela.mail@javerianacali.edu.co
dc.title.en-US.fl_str_mv	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
dc.title.es-ES.fl_str_mv	Eventos trombóticos en pacientes con síndrome antifosfolípido y su manejo profiláctico.
title	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
spellingShingle	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management. Moreno-Gomez , Freddy Síndrome antifosfolípido Trombosis Anticoagulantes orales directos Warfarina Hidroxicloroquina Omega 3 Antiagregantes plaquetarios Antiphospholipid syndrome Thrombosis Direct.acting oral anticoagulants Warfarin Hydroxycloroquine Omega 3 Antiplatelets
title_short	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
title_full	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
title_fullStr	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
title_full_unstemmed	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
title_sort	Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.
dc.creator.none.fl_str_mv	Moreno-Gomez , Freddy Avendaño-Restrepo, Manuela
author	Moreno-Gomez , Freddy
author_facet	Moreno-Gomez , Freddy Avendaño-Restrepo, Manuela
author_role	author
author2	Avendaño-Restrepo, Manuela
author2_role	author
dc.subject.es-ES.fl_str_mv	Síndrome antifosfolípido Trombosis Anticoagulantes orales directos Warfarina Hidroxicloroquina Omega 3 Antiagregantes plaquetarios
topic	Síndrome antifosfolípido Trombosis Anticoagulantes orales directos Warfarina Hidroxicloroquina Omega 3 Antiagregantes plaquetarios Antiphospholipid syndrome Thrombosis Direct.acting oral anticoagulants Warfarin Hydroxycloroquine Omega 3 Antiplatelets
dc.subject.en-US.fl_str_mv	Antiphospholipid syndrome Thrombosis Direct.acting oral anticoagulants Warfarin Hydroxycloroquine Omega 3 Antiplatelets
description	The antiphospholipid syndrome (APS) is a clinical condition whose main form of presentation is thrombosis of various vascular beds, leading to multiple complications that represent a threat to the life of patients. Therefore, the goal of this review is to present the current recommendations on the management of the syndrome, in addition to emphasizing the existence of therapeutic alternatives other than vitamin K inhibitors. The exploration of multiple international guidelines regarding the management of APS allowed to establish that Warfarin continues to be the pillar of management for the thrombotic manifestations of the disease, and DOACs aren´t recommended for patients with APS due to recurrent thrombosis associated to this product. More clinical trials and research are required to safely recommend the use of therapies other than Warfarin in APS.
publishDate	2022
dc.date.accessioned.none.fl_str_mv	2023-10-11T04:35:06Z
dc.date.available.none.fl_str_mv	2023-10-11T04:35:06Z
dc.date.none.fl_str_mv	2022-06-30
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
dc.type.es-ES.fl_str_mv	Revisión de la literatura
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/680
dc.identifier.uri.none.fl_str_mv	https://vitela.javerianacali.edu.co/handle/11522/481
url	https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/680 https://vitela.javerianacali.edu.co/handle/11522/481
dc.language.none.fl_str_mv	spa
language	spa
dc.relation.none.fl_str_mv	https://revistas.javerianacali.edu.co/index.php/salutemscientiaspiritus/article/view/680/578
dc.rights.es-ES.fl_str_mv	Derechos de autor 2023 Salutem Scientia Spiritus https://creativecommons.org/licenses/by-nc-nd/4.0
rights_invalid_str_mv	Derechos de autor 2023 Salutem Scientia Spiritus https://creativecommons.org/licenses/by-nc-nd/4.0
dc.format.none.fl_str_mv	application/pdf
dc.publisher.es-ES.fl_str_mv	Pontificia Universidad Javeriana Cali
dc.source.en-US.fl_str_mv	Salutem Scientia Spiritus; Vol. 8 No. 2 (2022): Revista Salutem Scientia Spiritus; 50-57
dc.source.es-ES.fl_str_mv	Salutem Scientia Spiritus; Vol. 8 Núm. 2 (2022): Revista Salutem Scientia Spiritus; 50-57
dc.source.none.fl_str_mv	2463-1426
institution	Pontificia Universidad Javeriana Cali
repository.name.fl_str_mv	Repositorio Vitela
repository.mail.fl_str_mv	vitela.mail@javerianacali.edu.co
_version_	1812095060676706304

Thrombotic events in patients with antiphospholipid syndrome and their prophylactic management.

Publicaciones similares